Allos Therapeutics, Inc. will unveil its latest earnings on Tuesday, March 6, 2012. Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer.
Allos Therapeutics, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for net loss of 8 cents per share, a narrower loss from the year-earlier quarter net loss of 17 cents. During the past three months, the average estimate has moved up from a loss of 11 cents. Between one and three months ago, the average estimate moved up. It has been unchanged at a loss of 8 cents during the last month.
Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 4 cents, reporting a loss of 11 cents per share against a mean estimate of net loss of 15 cents per share.
Investing Insights: Warren Buffett Trashes Gold, But What About Silver?
Wall St. Revenue Expectations: Analysts are projecting a rise of 36.2% in revenue from the year-earlier quarter to $15.9 million.
Analyst Ratings: Analysts seem relatively indifferent about Allos Therapeutics with four of five analysts surveyed maintaining a hold rating.
A Look Back: In the third quarter, the company’s loss narrowed to a loss of $11.2 million (11 cents a share) from a loss of $18.8 million (18 cents) a year earlier, beating analyst expectations. Revenue rose 72.5% to $14.2 million from $8.2 million.
The company has enjoyed double-digit year-over-year percentage revenue growth for the past four quarters. Over that span, the company has averaged growth of more than twofold, with the biggest boost coming in the second quarter when revenue rose more than fourfold from the year earlier quarter.
Stock Price Performance: Between December 1, 2011 and February 29, 2012, the stock price rose 13 cents (9.6%), from $1.36 to $1.49. The stock price saw one of its best stretches over the last year between September 9, 2011 and September 16, 2011, when shares rose for six straight days, increasing 18.8% (+27 cents) over that span. It saw one of its worst periods between November 14, 2011 and November 21, 2011 when shares fell for six straight days, dropping 11.5% (-17 cents) over that span.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Stories:
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com